![]() |
|
|
Vol. 61, Issue 4, 853-860, April 2002
Departments of Physiology and Pharmacology (O.B., N.R., J.J.G.M.) and Biochemistry and Molecular Biology (M.A.S.), University of Salamanca, Salamanca, Spain; Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, Zurich, Switzerland (B.H., P.J.M.); and Department of Anatomy, University of Würzburg, Würzburg, Germany (H.K.)
| |
Abstract |
|---|
|
|
|---|
Molecular bases for targeting bile acid-cisplatin derivatives Bamet-R2 [cis-diammine-chloro-cholylglycinate-platinum(II)] and Bamet-UD2 [cis-diammine-bisursodeoxycholate-platinum(II)] toward liver cells were investigated. Carriers for bile acids [human Na+-taurocholate cotransporting polypeptide (NTCP)], organic anions [organic anion transporting polypeptide (OATP)], and organic cations [organic cation transporter (OCT)] were expressed in Xenopus laevis oocytes (XO) and Chinese hamster ovary (CHO) cells. Drug uptake was measured by flameless atomic absorption of platinum. Rat Oatp1- or rat Ntcp-transfected CHO cells were able to take up Bamets, but not cisplatin, severalfold more efficiently than wild-type cells. This uptake was enhanced by butyrate-induced expression of both carriers. Uptake of both Bamets by Ntcp-transfected CHO cells was stimulated by extracellular sodium. The amount of Bamets, but not cisplatin, taken up by XO was enhanced when expressing OATP-A, OATP-C, NTCP, OCT1, or OCT2, a nonhepatic OCT isoform used for comparative purposes. Bamet uptake by XO was inhibited by known substrates of these carriers (glycocholate for NTCP and OATP-C, ouabain for OATP-A, and quinine for OCT1 and OCT2). Drug uptake versus substrate concentration revealed saturation kinetics (Km was in the 8-58 µM range), with the following order of efficiency of transport (Vmax/Km) for Bamet-R2: OATP-C > OCT2 > OATP-A > NTCP > OCT1; and the following order of efficiency of transport for Bamet-UD2: OATP-C > OCT2 > OATP-A > OCT1 > NTCP. Increasing the generation of cationic forms of Bamets by incubation in the absence of chloride increased drug uptake by OATP-A, OCT1, and OCT2 but reduced that achieved by NTCP and OATP-C. These results suggest a role for carriers of organic anions and cations in Bamet-R2 and Bamet-UD2 uptake, which may determine their ability to accumulate in liver tumor cells and/or be taken up and efficiently excreted by hepatocytes.
| |
Introduction |
|---|
|
|
|---|
The
liver plays a key role in the biotransformation and excretion of a
broad variety of xenobiotic and endogenous substances. Carrier proteins
mediate hepatic uptake of many of these anionic, neutral, and cationic
compounds from the blood. Among them, the Na+-taurocholate cotransporting polypeptide
(NTCP) is considered to be the major system accounting for the
Na+-dependent uptake of bile acids and perhaps
other organic anions (Hagenbuch and Meier, 1996
). A whole family of
Na+-independent carriers, the organic anion
transporting polypeptides (OATPs), of which numbers of
identified and cloned members are increasingly larger, contributes to
this task. These transporters, expressed in different tissues, are able
to carry out the uptake of a wide spectrum of structurally unrelated
compounds, such as bile acids, anionic conjugated and neutral steroids,
such as ouabain (Hagenbuch et al., 2000
). Some of them, however, such
as human OATP-A, also seem to be able to transport type-II organic
cations (Van Montfoort et al., 1999
; 2001
). Nevertheless, such
transport is probably accomplished mainly by carrier systems known as
organic cation transporters (OCTs), which have been found to be
involved in the hepatic clearance of many organic cations, including
several chemotherapeutic drugs (Koepsell, 1998
).
The use of specific transporters expressed in targeted cells has been
proposed as a promising strategy for tissue-selective drug delivery
(Tsuji, 1999
). Regarding this, the efficiency of hepatocytes in taking
up bile acids and other organic compounds, owing to the existence in
the basolateral plasma membrane of the above-mentioned multispecific
carrier systems, has been the basis for suggesting the use of these
hepatotropic compounds or their analogs as shuttles for delivering
different types of drugs to the liver (Ho, 1987
). Some examples of this
approach are the binding of inhibitors of hydroxymethylglutaryl (HMG)
CoA reductase (Wess et al., 1994
) or of cytostatic compounds (Kramer et
al., 1992
; Marin et al., 1998a
) to bile acids. Our group has
synthesized and characterized several members of a new family of
antitumoral compounds by binding cisplatin to the side chain of bile
acids (Criado et al., 1997a
,b
; 2000
). They have been designated as
Bamet, from "Ba," standing for the bile acid moiety, and "met,"
standing for the transition metal, which is the DNA-reactive moiety of these compounds (Marin et al., 1998b
; Criado et al., 2000
). The purpose
of this approach was to obtain analogs that could be recognized by
carrier proteins able to transport cholephilic compounds; this would
presumably enhance their vectoriality toward the hepatobiliary system.
Previous studies have shown that some of these drugs, such as
[cis-diammine-chloro-cholylglycinate-platinum(II)]
(Bamet-R2) and
[cis-diammine-bisursodeoxycholate-platinum(II)]
(Bamet-UD2), might be potentially useful in the chemotherapy of liver
tumors because of their liver organotropism (Marin et al., 1998a
;
Macias et al., 1999
), their strong cytostatic activity in vitro, and their antitumoral effect against tumors implanted in the liver of nude
mice (Marin et al., 1998b
; Larena et al., 2000
; Dominguez et al.,
2001
). Previous studies carried out with rat hepatocytes in primary
culture suggested an efficient uptake of Bamet-R2, probably via an
Na+-independent pathway (Macias et al., 1998
).
However, transport studies in intact cells fail to distinguish between
the contribution of one or more carrier systems involved in the overall
process, which may lead to mistaken conclusions. Elucidation of the
exact route used by Bamets to enter the cells is important to further develop new and more specific derivatives. The aim of this work, therefore, was to evaluate the role of carriers of organic anions and
cations in Bamet-R2 and Bamet-UD2 uptake, which may determine their
ability to reach liver tumor cells and/or be taken up and excreted by hepatocytes.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals.
Cisplatin, sodium glycocholate (GC), ouabain,
quinine hydrochloride, TEA, and cell culture medium were obtained from
Sigma-Aldrich (Madrid, Spain). GC was more than 95% pure by thin-layer
chromatography. Geneticin was from Roche Applied Science (Barcelona,
Spain). [14C]GC (55.0 mCi/mmol),
[3H]inulin (304.8 mCi/g),
[3H]ouabain (15.4 Ci/mmol), and
[14C]TEA (2.4 mCi/mmol) were purchased from
Pacisa & Giralt (Madrid, Spain). Bamet-R2 was synthesized by
binding GC to cisplatin as previously reported (Criado et al., 1997b
).
Bamet-UD2 was synthesized by binding two ursodeoxycholic acid molecules
to cisplatin (Criado et al., 2000
). All other reagents were of
analytical grade and were readily available from commercial sources.
Uptake Studies in CHO Cells.
Wild-type Chinese hamster ovary
(CHO) cells (CHO-K1), stably SLC10A1- or Ntcp-expressing CHO 9-6 cells
(Schroeder et al., 1998
) as well as stably SLC21A1- or Oatp1-expressing
CHO-03 cells (Eckhardt et al., 1999
), were cultured as described
previously (Schroeder et al., 1998
). In some sets of experiments, the
expression of Ntcp or Oatp1 was induced by incubating the cells with
culture medium supplemented with 5 mM sodium butyrate for 24 h
(Palermo et al., 1991
). To determine drug uptake by these cells,
experiments were carried out using four culture dishes (3 cm in
diameter) for each data point. Subconfluent cell cultures were rinsed
with uptake medium (116 mM NaCl or choline chloride, 5.3 mM KCl, 1.1 mM
KH2PO4, 1.8 mM
CaCl2, 11 mM D-glucose, and 10 mM
HEPES/Tris, pH 7.4), and the cells were subsequently incubated in the
presence of 50 µM concentrations of the desired compound at 37°C
for the time indicated in Figures 1, 2, and 3 in each case.
Uptake was stopped by rinsing the culture dishes four times with 2 ml
of ice-cold uptake medium containing 100 µM cholic acid to reduce nonspecific extracellular binding. Cells were digested in 1 ml of 0.7%
SDS. To measure platinum contents, 800-µl aliquots were mineralized
as described below. Protein concentrations were measured by the method
of Markwell et al. (1978)
.
Uptake Studies in Xenopus laevis Oocytes.
Synthesis of cRNA for injection into oocytes was performed using
recombinant plasmids containing the cDNA of NTCP (SLC10A1), OATP-A
(SLC21A3), OATP-C (SLC21A6), OCT1 (SLC22A1), or OCT2 (SLC22A2). These
plasmids were isolated from Escherichia coli using the
QIAGEN Plasmid Mini Kit (QIAGEN, Barcelona, Spain) and further
linearized with restriction enzymes (Roche Applied Science). cRNAs were
synthesized using the T7 mMessage mMachine kit (Ambion, Austin, TX).
Mature female X. laevis frogs from Regine Olig (Hamburg,
Germany) were anesthetized by intramuscular administration (in the leg)
of 12.5 mg of ketamine (Imalgène 500; Rhône Mérieux,
Barcelona, Spain). Animals received humane care as outlined in the
Guide for the Care and Use of Laboratory Animals (Unites States
National Institutes of Health Publication 80-23, revised 1985). The
University of Salamanca Ethical Committee for Laboratory Animals
approved the experimental protocol. Harvesting and preparation of
oocytes were carried out by a modification of the method described in
detail by Hagenbuch et al. (1990)
. Briefly, a portion of ovarian tissue was removed, and individual oocytes were isolated and defolliculated by
incubation with collagenase (2 mg/ml) in calcium-free buffer for 45 min
at 20°C and incubated overnight at 18°C in modified Barth's
solution: 88 mM NaCl, 2.4 mM NaHCO3, 1 mM KCl,
0.3 mM Ca(NO3)2, 0.41 mM
CaCl2, 0.82 mM MgSO4, 50 mg/l gentamicin, and 15 mM HEPES, pH 7.6. Oocytes with a normal shape
and color were considered healthy and were injected with 7 ng of
carrier protein cRNA dissolved in 14 nl of TE buffer (1 mM EDTA and 10 mM Tris, pH 8.0), or TE buffer alone, used as a control to determine
nonspecific uptake of the substrates. The oocytes were subsequently
cultured in modified Barth's solution for 2 days at 18°C. To carry
out uptake studies, groups of between 10 and 20 oocytes were prewashed in the uptake medium containing 2 mM KCl, 1 mM
CaCl2, 1 mM MgCl2, 10 mM
HEPES/Tris, pH 7.5, and 100 mM choline chloride. To determine Na+-dependent uptake by NTCP-expressing oocytes,
they were incubated with medium containing either 100 mM NaCl or 100 mM
choline chloride. In experiments designed to measure Bamet uptake in
the absence of chloride, the composition of the uptake medium was 2 mM
KNO3, 1 mM
Ca(NO3)2, 1 mM
MgSO4, 100 mM NaNO3, or 100 mM KNO3 to measure Na+-dependent uptake in NTCP-expressing oocytes,
and 10 mM HEPES/Tris, pH 7.5. The oocytes were then incubated for the
desired time at 25°C in 100 µl of the uptake medium containing the
compound to be tested. Uptake was stopped by the addition of 4 ml of
ice-cold uptake medium containing 100 µM cholic acid. Oocytes were
washed an additional three times with this solution and then collected individually, placed in individual vials, and dissolved with 200 µl
of 1% SDS solution.
Analytical and Statistical Methods. Bamet-R2, Bamet-UD2, and cisplatin concentrations were determined by measuring platinum by flameless atomic absorption spectrophotometry (Z-8100 Polarized Zeeman apparatus with a graphite furnace; Hitachi, Tokyo, Japan). To measure platinum contents, samples were mineralized in pure HNO3 at 80°C for 2 h and then at 150°C until dryness. Before being measured, samples were redissolved with 20 mM HCl at 60°C for 4 h. Radioactivity was measured on a liquid scintillation counter (LS-6500; Beckman Coulter, Inc., Madrid, Spain). Unless otherwise indicated, results are expressed as mean ± S.E.M. For kinetic analyses, values were fitted to a Michaelis-Menten equation with or without an additional diffusional term. Estimations made by linear and nonlinear regression analysis were obtained using the UltraFit v2.1 software (Elsevier-Biosoft, Cambridge, UK). To calculate the statistical significance of the differences between groups, paired or unpaired Student's t tests were used as appropriate. The Bonferroni method was used for multiple-range testing. Statistical analysis was performed on a Power Macintosh 6400/200 (Apple, Cupertino, CA).
| |
Results |
|---|
|
|
|---|
Two different experimental models of the functional expression of
membrane carrier proteins were used in this study to investigate the
ability of these transport systems to mediate Bamet-R2 and Bamet-UD2
uptake. On the one hand, CHO cells stably transfected with cDNA of rat
carriers were used as an initial approach to identify the role of rat
carriers for cholephilic anions in Bamet uptake. Previous studies using
this mammalian expression system have shown that Oatp1- and
Ntcp-expressing CHO cells, but not wild-type cells, exhibit an
efficient uptake of bile acids, such as GC, among several other
substrates (Schroeder et al., 1998
; Eckhardt et al., 1999
). The results
of time-course studies of Bamet-R2 and Bamet-UD2 uptake in both
wild-type (CHO-K1) and Oatp1-expressing (CHO-03) CHO cells are compared
in Fig. 1. Uptake by CHO-03 cells of both
Bamets was approximately 6-fold higher than their levels in wild-type
CHO-K1 cells. In the presence of Na+,
Ntcp-expressing CHO 9-6 cells were able to carry out the uptake of
Bamet-R2 and Bamet-UD2 at amounts 5- and 8-fold higher than wild-type
cells, respectively (Fig. 2). This was
markedly reduced when Na+ was removed from the
incubation medium, whereas the absence of sodium did not affect drug
retention by wild-type cells (Fig. 2).
|
|
The presence of sodium butyrate in the culture medium of CHO cells,
which has been shown to enhance expression of recombinant proteins
(Palermo et al., 1991
), has been used previously to increase both Oatp1
(Eckhardt et al., 1999
) and Ntcp (Schroeder et al., 1998
) expression in
stably transfected CHO cells. In our hands, this maneuver markedly
enhanced GC, Bamet-R2, and Bamet-UD2 uptake by cells transfected with
cDNA of Oatp1 or Ntcp, regarding both at steady-state (Fig.
3) and initial uptake rates (data not
shown) compared with cell cultures where butyrate had been removed. By contrast, no effect of preincubation with butyrate on GC, Bamet-R2, and
Bamet-UD2 uptake by wild-type CHO-K1 cells was observed (Fig. 3).
|
Finally, we investigated whether GC, a substrate of both Oatp1 and
Ntcp, was able to inhibit Bamet uptake by CHO cells expressing one of
these carriers. The results indicated that GC reduced the amount of
Bamet-R2 (
75%) and Bamet-UD2 (
44%) taken up by Oatp1-transfected CHO cells. GC also induced cis-inhibition of Bamet-R2
(
40%) and Bamet-UD2 (
46%) uptake by Ntcp-expressing cells (Table
1).
|
An X. laevis oocyte expression system was used as an
additional experimental model that permitted us to study Bamet
transport by human carriers, including transporters of organic cations, and to carry out kinetic analyses. Oocytes were injected with the cRNA
of the human transporters NTCP, OATP-A, OATP-C, OCT1, or OCT2. Although
OCT2 is not expressed in the liver, it was included in the study for
comparative purposes and because the kidney is the other organ, besides
the liver, where Bamets are transiently accumulated (Dominguez et al.,
2001
). Before using this model, suitable expression of the carrier
proteins in the X. laevis oocytes was confirmed in uptake
experiments (data not shown) using prototypic radiolabeled substrates
of these transporters, namely, conjugated cholic acid for NTCP (Meier
et al., 1997
) and OATP-C (Abe et al., 1999
), ouabain for OATP-A
(Hagenbuch and Meier, 1996
), and TEA for OCT1 and OCT2 (Koepsell,
1998
). Preliminary studies on the time course of functional expression
(data not shown) revealed that the highest uptake rate was obtained 2 or 3 days after injecting the cRNA of each protein. Therefore, all
uptake experiments were carried out at the time after injection that
was most appropriate for each protein.
The amount of cisplatin taken up by oocytes expressing OATP-A, OATP-C,
NTCP, OCT1, or OCT2 was not higher than that observed in oocytes
injected with TE buffer, considered as the control group (Fig.
4A). Thus, no significant changes in the
amount of cisplatin taken up by the oocytes were found in the presence
or absence of typical substrates of the expressed transporters (Fig. 4A). These results clearly indicated that cisplatin is not transported by these carrier systems.
|
By contrast, uptake of both Bamet-R2 (Fig. 4B) and Bamet-UD2 (Fig. 4C) by OATP-A, OATP-C, NTCP, OCT1, or OCT2 cRNA-injected oocytes was higher than drug uptake by TE-injected control oocytes. In general, uptake by these carriers was higher for Bamet-UD2 than for Bamet-R2. Furthermore, the presence of known substrates of the transporters expressed in oocytes at concentrations 10-fold higher than that of the Bamet resulted in a marked inhibition of Bamet-R2 or Bamet-UD2 uptake.
To carry out kinetic studies, oocytes were incubated in the presence of
several substrate concentrations for 10 min; based on the results from
studies on time course uptake (Fig. 5),
this was considered the right time to determine drug uptake under
initial velocity conditions. Kinetic analyses revealed the existence of a saturable uptake process for Bamet-R2 (Fig.
6A) and Bamet-UD2 (Fig. 6B) by all
carriers studied. Comparison of the values found for the apparent
affinity constant for each carrier indicated that the order of affinity
for Bamet-R2 was OATP-C
OCT2 > OATP-A
NTCP > OCT1 and for Bamet-UD2 was OCT2
OATP-C > OATP-A
OCT1 > NTCP (Table 2).
Calculation of efficiency of transport
(Vmax/Km) revealed the following order for Bamet-R2: OATP-C > OCT2 > OATP-A > NTCP > OCT1 and the following order for Bamet-UD2:
OATP-C > OCT2 > OATP-A > OCT1 > NTCP. This also
indicated that Bamet-UD2 is a better substrate than Bamet-R2 for all
these carriers.
|
|
|
To elucidate whether the cationic or the neutral form of these
compounds was the best substrate for each carrier, uptake of both
Bamet-R2 and Bamet-UD2 was studied in the absence of chloride, which is
expected to increase the formation of the cationic form of these types
of compounds due to replacement of chloride by an "aquo" group.
Thus, the increase in the proportion of cationic forms of Bamets in the
mixture had no effect on nonspecific uptake in TE-injected oocytes but
significantly enhanced the uptake of Bamet-R2 (Fig.
7A) and Bamet-UD2 (Fig. 7B) by oocytes
expressing OCT2, OATP-A, and, to a lesser extent, OCT1, although it
caused a moderate decrease in Na+-dependent
uptake by NTCP and in Na+-independent uptake by
OATP-C.
|
| |
Discussion |
|---|
|
|
|---|
This study provides molecular bases for understanding targeting of
Bamets toward normal liver and tumor cells derived from the
enterohepatic circuit (Monte et al., 1999
). Among other members of this
family of drugs, Bamet-R2 and Bamet-UD2 exert the strongest in vitro
cytostatic (Marin et al., 1998b
; Martinez-Diez et al., 2000
) and in
vivo antitumor (Dominguez et al., 2001
) effects. Although they share
the antiproliferative capacity characteristic of cisplatin, both are
much less toxic. This is partly because of the enhanced liver
organotropism, which determines efficient excretion into bile together
with lower drug exposure of other organs, including the kidney (Macias
et al., 1999
; Dominguez et al., 2001
).
The most important structural difference among these drugs is the
presence of bile acid moieties in Bamets that are absent in cisplatin.
On the other hand, they share important characteristics; i.e., they are
neutral compounds that in aqueous solution undergo replacement of some
of the platinum(II) ligands by water. This results in the formation of
"aquo" groups that are DNA-reactive (for a review, see Sundquist
and Lippard, 1990
). Most of this process probably occurs within cells,
where chloride concentrations are lower than those in plasma. Simple
diffusion of the extracellular neutral cisplatin form is believed to be
the main pathway for cisplatin uptake; however, a role of mediated
transport by mechanisms similar to those of neutral amino acid uptake
has been suggested (Chu, 1994
). Bamets are also activated to form
DNA-reactive "aquo" groups in aqueous solution. In Bamet-R2, this
occurs through replacement of the chloride ion present in the neutral
form, thus resulting in a monocationic derivative (Criado et al.,
1997b
). It could be expected that, as in the case of cisplatin, this
would occur within the cell. However, the transformation of Bamet-R2 is
faster in 150 mM NaCl than in pure water (Criado et al., 1997b
),
implying that cationic forms of Bamet-R2 should be formed even in the
extracellular fluid. Bamet-UD2 is also activated in 150 mM NaCl to a
monocationic derivative; in this case, however, the mechanism is the
release of one of the ursodeoxycholate moieties (Criado et al., 2000
).
The finding that, unlike both Bamets, cisplatin was not transported by
any of the rat or human carriers that have been assayed indicates that
the presence of the bile acid moiety in Bamets is crucial for these
compounds to be transported by these carriers. Moreover,
Km values for both drugs are similar
to those found for established substrates [i.e., 17
-glucuronosyl
estradiol/OATP-C, Km = 8.2 µM
(König et al., 2000
); bromosulfophthalein/OATP-A, Km = 20 µM (Kullak-Ublick et al.,
1995
); taurocholate/NTCP, Km = 6 µM
(Hagenbuch and Meier, 1994
); methyl-4-phenylpyridinium/OCT1, Km = 14.6 µM (Zhang et al., 1997
);
and TEA/OCT2: Km = 76 µM (Gorboulev et al., 1997
), which indicates that Bamet-R2 and Bamet-UD2 are good
substrates for these carriers.
The ability of OCT1 and OCT2 to take up the Bamets was not surprising,
because in aqueous solution, these compounds are in part as cationic
forms. Moreover, overlapping substrate specificity of both carriers has
been reported (Okuda et al., 1999
). Because OCT1 is expressed in the
liver and the kidney, whereas OCT2 is expressed only in the kidney
(Gorboulev et al., 1997
), OCT1 may contribute to the liver uptake of
these drugs, whereas both OCT1 and OCT2 may play a role in Bamet uptake
by the kidney (Dominguez et al., 2001
). On the contrary, cisplatin was
not a good substrate for OCT1 or OCT2, which suggests that these
carriers are not involved in the marked renal accumulation of cisplatin
(Dominguez et al., 2001
).
Although most of the known substrates for members of OATP family are
organic anions, these transporters are also able to transport both
organic cations (Van Montfoort et al., 1999
) and neutral compounds
(Hagenbuch et al., 2000
). This suggests that both neutral and cationic
forms of Bamets are also candidate substrates for these carriers. This
is consistent with enhanced uptake of Bamets by OATP-A in the absence
of chloride. However, this maneuver decreased uptake by OATP-C, which
suggests that this carrier does prefer the neutral form of Bamets.
The nonsubstituted bile acid side chain with monoanionic charge is
important for substrate interactions with ileal and hepatic Na+-dependent bile acid carriers (Baringhaus et
al., 1999
). Moreover, it was reported that Bamet-R2 was taken up by rat
hepatocytes in primary culture mainly via
Na+-independent mechanisms (Macias et al., 1998
).
However, the results obtained in the present work suggest that Ntcp and
NTCP can mediate Bamet uptake. Two facts may partly explain this
apparent controversy. First, the expression of Ntcp falls dramatically
after culturing rat hepatocytes (Liang et al., 1993
). Second, if the
contribution of Ntcp to the overall uptake of Bamet-R2 by rat
hepatocytes is low compared with other
Na+-independent pathways, which is consistent
with our results, this might enhance the difficulty in observing a
reduction in Bamet uptake when sodium was replaced by choline in the
incubation medium. Regarding the second controversial issue, other
authors have also observed that Ntcp is probably able to transport
neutral steroids with lower efficiency than anionic steroids (Schroeder
et al., 1998
) but not cationic bile acid derivatives (Anwer et al.,
1985
). This suggests, but does not prove, that the form of the Bamets transported by this carrier may be the neutral one. This is in agreement with the fact that displacement toward the cationic forms by
the removal of chloride ions from the incubation medium induced a
reduction in Bamet uptake by NTCP.
Certain cell lines derived from liver tumors have, to a certain extent,
lost their ability to take up bile acids. However, molecular evidence
for the expression of both NTCP and a member of the OATP family in
human hepatocellular carcinoma cells has been found (Kullak-Ublick et
al., 1997
). Moreover, the ability to take up bile acid derivatives is
still present, although lower than that of hepatocytes, in human
(Kullak-Ublick et al., 1997
) and rat liver tumor cells (Monte et al.,
1999
). Moreover, the expression of OCT1 is preserved in chemically
induced rat malignant liver lesions (Lecureur et al., 1998
). Those
findings, together with these of the present work, support the
hypothesis that coupling of drugs to the side chain of bile acids may
be a useful pharmacological strategy to target them toward liver tumor
cells. However, to obtain a complete picture of this issue, screening
of the presence and preserved functionality of appropriate carriers in
the plasma membrane of cells collected from human tumors is needed.
In sum, these results indicate that marked liver organotropism of Bamet-R2 and Bamet-UD2 probably exists because these compounds are efficiently transported by several carrier systems for organic anions and cations expressed in the plasma membrane of hepatocytes. However, it should be kept in mind that organ specificity for a given substrate is probably generated by a combination of factors that include the expression levels of each contributing carrier and the functional balance between import carriers and export pumps.
| |
Acknowledgments |
|---|
We thank L. Muñoz, J.F. Martin, J. Villoria, and A. Pascua for care of the animals; secretarial help by M. I. Hernandez and revision of the English version of the manuscript by N. Skinner are also gratefully acknowledged.
| |
Footnotes |
|---|
Received July 30, 2001; Accepted January 4, 2002
This study was supported in part by the Junta de Castilla y León (grant SA0298), Programa Fondo Europeo de Desarrollo Regional del Plan Nacional de I+D (grant 1FD97-0389), and Comisión Interministerial de Ciencia y Tecnología (grant SAF96-0146).
Address correspondence to: Dr. Jose J.G. Marin, Departamento de Fisiología y Farmacología, Campus Miguel de Unamuno, ED-S09, 37007 Salamanca, Spain. E-mail: jjgmarin{at}gugu.usal.es
| |
Abbreviations |
|---|
Ntcp, rat Na+-taurocholate cotransporting polypeptide; Oatp, rat organic anion transporting polypeptide; OATP, human organic anion transporting polypeptide; OCT, human organic cation transporter; HMG, hydroxymethylglutaryl; Bamet-R2, cis-diammine-chloro-cholylglycinate-platinum(II); Bamet-UD2, cis-diammine-bisursodeoxycholate-platinum(II); GC, glycocholate; TEA, tetraethylammonium; TE, Tris/EDTA; CHO, Chinese hamster ovary; NTCP, human Na+-taurocholate cotransporting polypeptide.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
O. Briz, M. R. Romero, P. Martinez-Becerra, R. I. R. Macias, M. J. Perez, F. Jimenez, F. G. S. Martin, and J. J. G. Marin OATP8/1B3-mediated Cotransport of Bile Acids and Glutathione: AN EXPORT PATHWAY FOR ORGANIC ANIONS FROM HEPATOCYTES? J. Biol. Chem., October 13, 2006; 281(41): 30326 - 30335. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zhang, K. S. Lovejoy, J. E. Shima, L. L. Lagpacan, Y. Shu, A. Lapuk, Y. Chen, T. Komori, J. W. Gray, X. Chen, et al. Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity. Cancer Res., September 1, 2006; 66(17): 8847 - 8857. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Monte, M. R. Ballestero, O. Briz, M. J. Perez, and J. J. G. Marin Proapoptotic Effect on Normal and Tumor Intestinal Cells of Cytostatic Drugs with Enterohepatic Organotropism J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 24 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chang, K. S. Pang, P. W. Swaan, and S. Ekins Comparative Pharmacophore Modeling of Organic Anion Transporting Polypeptides: A Meta-Analysis of Rat Oatp1a1 and Human OATP1B1 J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 533 - 541. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of Drug Transporter Studies on Drug Discovery and Development Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Briz, R. I. R. Macias, M. Vallejo, A. Silva, M. A. Serrano, and J. J. G. Marin Usefulness of Liposomes Loaded with Cytostatic Bile Acid Derivatives to Circumvent Chemotherapy Resistance of Enterohepatic Tumors Mol. Pharmacol., March 1, 2003; 63(3): 742 - 750. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||